Physician response to implementation of genotype-tailored antiplatelet therapy-Reference-Cited by-同舟云学术

Physician response to implementation of genotype-tailored antiplatelet therapy

Published:2016-02-17 Issue:1 Volume:100 Page:67-74
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Peterson JF¹²,Field JR³,Unertl KM¹,Schildcrout JS⁴⁵,Johnson DC⁶,Shi Y⁴,Danciu I¹³,Cleator JH²⁷,Pulley JM³,McPherson JA²,Denny JC¹²,Laposata M⁸,Roden DM²⁷,Johnson KB¹⁹

Affiliation:

1. Department of Biomedical Informatics; Vanderbilt University School of Medicine; Nashville Tennessee USA

2. Department of Medicine; Vanderbilt University School of Medicine; Nashville Tennessee USA

3. Institute of Clinical and Translational Research; Vanderbilt University School of Medicine; Nashville Tennessee USA

4. Department of Biostatistics; Vanderbilt University School of Medicine; Nashville Tennessee USA

5. Department of Anesthesiology; Vanderbilt University School of Medicine; Nashville Tennessee USA

6. Department of Pharmacy; Vanderbilt University Medical Center; Nashville Tennessee USA

7. Department of Pharmacology; Vanderbilt University School of Medicine; Nashville Tennessee USA

8. Department of Pathology; Microbiology, and Immunology, Vanderbilt University School of Medicine; Nashville Tennessee USA

9. Department of Pediatrics; Vanderbilt University School of Medicine; Nashville Tennessee USA

Funder

Vanderbilt University

The Centers for Disease Control and Prevention

The National Heart, Lung, And Blood Institute

The National Institute for General Medical Sciences

The National Human Genome Research Institute

The National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.331/fullpdf

Reference37 articles.

1. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008;Gu;NCHS Data Brief,2010

2. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States;JAMA,2008

3. Pharmacogenomic Biomarkers in Drug Labels FDA Pharmacogenomic Biomarkers in Drug Labeling http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm

4. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey;Stanek;Clin. Pharmacol. Ther.,2012

5. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network;Relling;Clin. Pharmacol. Ther.,2011

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications;Interventional Cardiology Clinics;2024-10

2. Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review;Therapeutic Drug Monitoring;2024-09-11

3. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

4. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data;The Pharmacogenomics Journal;2024-05-15

5. Early evaluation of a novel alert within cardiac procedural areas to facilitate genotype‐guided antiplatelet therapy;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-05-03